Journal article icon

Journal article

Tryptophan 2,3-dioxygenase expression identified in human hepatocellular carcinoma cells and in intratumoral pericytes of most cancers

Abstract:

Tryptophan catabolism is used by tumors to resist immune attack. It can be catalyzed by indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase (TDO). IDO1 is frequently expressed in tumors and has been widely studied as a potential therapeutic target to reduce resistance to cancer immunotherapy. In contrast, TDO expression in tumors is not well characterized. Several human tumor cell lines constitutively express enzymatically active TDO. In human tumor samples, TDO expression has p...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1158/2326-6066.cir-19-0040

Authors


More by this author
Role:
Author
ORCID:
0000-0003-0694-1947
Publisher:
American Association for Cancer Research
Journal:
Cancer Immunology Research More from this journal
Volume:
8
Issue:
1
Pages:
19-31
Publication date:
2019-12-05
Acceptance date:
2019-11-15
DOI:
EISSN:
2326-6074
ISSN:
2326-6066
Pmid:
31806639
Language:
English
Keywords:
Pubs id:
pubs:1077162
UUID:
uuid:ac3048d5-28b8-4933-982b-6cc7785facb7
Local pid:
pubs:1077162
Source identifiers:
1077162
Deposit date:
2019-12-13

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP